FIG. 6.
Targeting IL-13Rα2-positive tumors cells in vivo, using a subcutaneous tumor model. (A) U251 cells were transduced with various amounts of the GLuc-encoding lentiviral vector pseudotyped with MV HcΔ18-AA-IL-13 and FcΔ30 glycoproteins and assayed for luciferase activity 3 days after transduction. (B) U251 cells and DU145 cells were transduced with an EGFP-encoding lentiviral vector pseudotyped with MV HcΔ18-AA-IL-13/FcΔ30 glycoproteins and analyzed as described for Fig. 2C. (C) Mice bearing subcutaneous U251 glioma cell-induced tumors or DU145 prostate carcinoma cell-induced tumors were injected with GLuc-encoding lentiviral vectors pseudotyped with the MV HcΔ18-AA-IL-13/FcΔ30 glycoproteins; vectors were administered directly into the tumors. Control injections consisted of PBS. Three days later, the mice were imaged with the IVIS system after 100 μl (2.5 mg/ml) of the coelenterazine substrate was injected into the tumors. Color images available online at www.liebertpub.com/hgtb